Sept 7 (Reuters) - Bubs Australia (BUB) :
- BUBS ANNOUNCES US-BASED INFANT FORMULA CLINICAL TRIAL
- PLANS TO SUBMIT RESULTS FROM GMS TO FDA BY SEPTEMBER 2024 WITH A FULL INFANT FORMULA SUBMISSION BY OCTOBER 2024
- BUBS IS ACTIVELY TAKING STEPS TO TRANSITION FROM TEMPORARY 'ENFORCEMENT DISCRETION' TO A PERMANENT MARKET POSITION
- STUDY DESIGNED TO EVALUATE GROWTH, TOLERANCE, AND SAFETY OF NEW INFANT FORMULAS
News: BUB Bubs Australia Says Us-Based Infant Formula Clinical Trial
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
15.0¢ |
Change
0.005(3.45%) |
Mkt cap ! $134.1M | |||
| Open | High | Low | Value | Volume |
| 15.0¢ | 15.0¢ | 14.5¢ | $122.2K | 828.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 372990 | 14.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 15.0¢ | 497553 | 8 |
View Market Depth
| Last trade - 16.10pm 19/09/2025 (20 minute delay) ? |
| BUB (ASX) Chart |